Mineralys Therapeutics, Inc.
$25.13
The Read: Mineralys Therapeutics’ stock has historically surged up to about 75% on positive FDA NDA acceptance and strong Phase 3 blood pressure data but also dropped around 18% when Phase 2 Explore-OSA trial failed primary endpoints and during dilutive financing announcements.
Price
Overlays
Panel
MLYS
Hover to view data
No Data